Efficacy of lanreotide autogel/depot (LAN) vs placebo (PBO) for symptomatic control of carcinoid syndrome (CS) in neuroendocrine tumor (NET) patients from the ELECT Meeting Abstract

sustainable development goals

publication date

  • October 1, 2016

webpage

published in

volume

  • 27